Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CLSA Raises ALI HEALTH's TP to HKD6.5; Original/ Innovative Drugs See Strong Sales & Sustained Growth
Recommend 17 Positive 33 Negative 16 |
||||
|
||||
|
According to CLSA's report, ALI HEALTH (00241.HK) raised its FY26 revenue growth guidance to 10-20% from 5-10% and adjusted net profit growth guidance to 20-30% from 10-20%, primarily due to better-than-expected sales performance of original and innovative drugs (especially GLP-1 medications). The strong sales data from ALI HEALTH and JD HEALTH (06618.HK) confirm the accelerating and sustainable trend of prescription drug outflow. As original and innovative pharmaceutical companies expand new sales channels, online platforms like Alibaba Health and JD Health have become the biggest beneficiaries. CLSA raised its target price for ALI HEALTH from HKD4.8 to HKD6.5 and kept the Outperform rating unchanged. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
